In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, ...
Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research ...
Bio-Techne Corporation (NASDAQ:TECH) is one of the most profitable biotech stocks to invest in now. On July 9, TD Cowen analyst Daniel Brennan initiated a new Buy rating on Bio-Techne Corporation ...
The FDA has granted Breakthrough Device Designation to Bio-Techne's (NASDAQ:TECH) ExoDx Prostate IntelliScore (EPI) test. Breakthrough Device status provides for more intensive guidance on development ...
Visualizes functional protein-protein interactions directly within fixed tissue at subcellular resolution Enables simultaneous detection of protein proximity, RNA, and proteins on the same tissue ...
(RTTNews) - Gemini Bioproducts, LLC, a supplier of cell culture reagents and process liquids and healthcare private equity firm BelHealth Investment Partners, LLC announced acquisition of selected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results